Segment Information and Concentration of Business Risk (Tables)

6 Months Ended

Jun. 30, 2017

Segment Information and Concentration of Business Risk [Abstract]

Segment Information

The following table shows our segment revenue and income (loss) from operations for the three and six months ended June 30, 2017 (in thousands), respectively.

Three Months Ended June 30, 2017	Ionis Core		Akcea Therapeutics			Elimination of Intercompany Activity			Total
Revenue:
Commercial revenue:
SPINRAZA royalties	$	22,366	$	—		$	—		$	22,366
Licensing and other royalty revenue		557		—			—			557
Total commercial revenue		22,923		—			—			22,923
R&D revenue under collaborative agreements		70,031		14,128			(2,930	)		81,229
Total segment revenue	$	92,954	$	14,128		$	(2,930	)	$	104,152
Total operating expenses	$	83,381	$	25,402		$	(2,960	)	$	105,823
Income (loss) from operations	$	9,573	$	(11,274	)	$	30		$	(1,671	)

Three Months Ended June 30, 2016	Ionis Core			Akcea Therapeutics			Elimination of Intercompany Activity			Total
Revenue:
R&D revenue under collaborative agreements	$	22,455		$	—		$	—		$	22,455
Licensing and other royalty revenue		16,015			—			—			16,015
Total segment revenue	$	38,470		$	—		$	—		$	38,470
Total operating expenses	$	72,622		$	14,805		$	(30	)	$	87,397
Loss from operations	$	(34,152	)	$	(14,805	)	$	30		$	(48,927	)

Six Months Ended June 30, 2017	Ionis Core		Akcea Therapeutics			Elimination of Intercompany Activity			Total
Revenue:
Commercial revenue:
SPINRAZA royalties	$	27,577	$	—		$	—		$	27,577
Licensing and other royalty revenue		4,103		—			—			4,103
Total commercial revenue		31,680		—			—			31,680
R&D revenue under collaborative agreements		213,457		23,725			(54,406	)		182,776
Total segment revenue	$	245,137	$	23,725		$	(54,406	)	$	214,456
Total operating expenses	$	161,733	$	94,872		$	(54,467	)	$	202,138
Income (loss) from operations	$	83,405	$	(71,147	)	$	60		$	12,318

Six Months Ended June 30, 2016	Ionis Core			Akcea Therapeutics			Elimination of Intercompany Activity			Total
Revenue:
R&D revenue under collaborative agreements	$	57,670		$	—		$	—		$	57,670
Licensing and other royalty revenue		17,675			—			—			17,675
Total segment revenue	$	75,345		$	—		$	—		$	75,345
Total operating expenses	$	148,135		$	30,847		$	(60	)	$	178,922
Loss from operations	$	(72,790	)	$	(30,847	)	$	60		$	(103,577	)

The following table shows our total assets by segment at June 30, 2017 and December 31, 2016 (in thousands), respectively.

Total Assets	Ionis Core		Akcea Therapeutics		Elimination of Intercompany Activity			Total
June 30, 2017	$	1,227,050	$	124,104	$	(260,323	)	$	1,090,831
December 31, 2016	$	1,067,770	$	10,684	$	(165,987	)	$	912,467

Revenue from Significant Partners

We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as ten percent or more of our total revenue, was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Partner A		76 %		25 %		46 %		41 %
Partner B		14 %		0 %		11 %		0 %
Partner C		1 %		10 %		31 %		7 %
Partner D		0 %		39 %		0 %		20 %